Expert Video - What is the outlook for patients with AML?
Dr. David Steensma explains that the outlook, or prognosis, varies widely from cure to a few months or years of life. The factors influencing the outlook include age, type of AML (AML subtype), general health and genetic changes present in the blasts. Younger patients and those with de novo AML often do better than those with treatment-related AML (tAML) or AML with myelodysplastic changes (AML-MRC).
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.